Vertex Pharmaceuticals Incorporated
VRTX
$472.41
-$5.48-1.15%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 30.46% | 3.59% | 128.74% | -41.22% | -5.76% |
| Total Depreciation and Amortization | 15.02% | 1.50% | -4.26% | -9.53% | -54.87% |
| Total Amortization of Deferred Charges | 23.81% | -- | -- | -- | 113.56% |
| Total Other Non-Cash Items | 7.39% | -139.67% | 341.24% | 1,522.73% | 305.47% |
| Change in Net Operating Assets | -69.19% | -5.02% | 45.15% | -307.66% | 33.22% |
| Cash from Operations | -14.81% | -9.37% | 128.59% | -37.33% | 149.19% |
| Capital Expenditure | -61.34% | -50.37% | -111.16% | 40.50% | -59.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 80.98% | 94.58% | 14.16% | 99.27% | 11.96% |
| Cash from Investing | 64.95% | 66.38% | -4.49% | 97.39% | 7.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.69% | 74.07% | 90.51% | 90.15% | 89.17% |
| Issuance of Common Stock | 57.43% | -5.95% | -10.73% | -1.18% | -26.08% |
| Repurchase of Common Stock | 69.21% | -196.91% | 0.77% | -91.01% | -178.45% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 22.22% | 22.22% | -22.22% | -77.14% | 160.00% |
| Cash from Financing | 80.27% | -197.94% | 2.62% | -90.32% | -226.63% |
| Foreign Exchange rate Adjustments | 115.43% | -117.98% | 2,388.00% | 295.51% | -272.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 120.71% | -105.20% | 106.48% | 109.41% | 9.19% |